Generic Medicine Info
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Angle-closure glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, bladder neck obstruction or predisposition to urinary retention. Patient undergoing treatment for acute asthmatic attack. Newborn or premature infants; elderly and debilitated patients. Lactation. Concomitant use with MAOIs.
Special Precautions
Patient with CV disease, including hypertension and ischaemic heart disease; thyroid dysfunction (e.g. hyperthyroidism), history of bronchial asthma, other chronic breathing disorders; increased intraocular pressure, acute porphyria. Hepatic impairment. Children (≥2 years). Pregnancy. Patient Counselling This drug may cause dizziness, drowsiness, or sedation; if affected, do not drive or operate machinery. Monitoring Parameters Monitor weight periodically; excess anticholinergic effects at the start of treatment and periodically thereafter.
Adverse Reactions
Significant: CNS depression (e.g. dizziness, sedation), hypotension; excitation (in children). Blood and lymphatic system disorders: Rarely, blood dyscrasias in prolonged use (e.g. leucopenia, haemolytic anaemia, agranulocytosis, thrombocytopenia). Cardiac disorders: Palpitation, extrasystoles, tachycardia. Ear and labyrinth disorders: Tinnitus, vertigo, acute labyrinthitis. Eye disorders: Blurred vision, diplopia. Gastrointestinal disorders: Dry mouth, nausea, vomiting, diarrhoea, constipation, epigastric distress. General disorders and administration site conditions: Fatigue, rigors. Hepatobiliary disorders: Jaundice, hepatitis, cholestasis, hepatic failure. Immune system disorders: Allergic reactions (e.g. rash, oedema), anaphylactic shock. Investigations: Weight gain, abnormal hepatic function. Metabolism and nutrition disorders: Increased appetite, anorexia. Nervous system disorders: Drowsiness, headache, tremor, restlessness, paraesthesia, convulsion, disturbed coordination, neuritis. Psychiatric disorders: Confusion, insomnia, nervousness, hallucination, euphoria, irritability, aggressive behaviour, hysteria. Renal and urinary disorders: Urinary retention, frequency or difficulty in micturition. Reproductive system and breast disorders: Early menses. Respiratory, thoracic and mediastinal disorders: Dry nose and throat, chest tightness and wheezing, nasal stuffiness, epistaxis, thickened bronchial secretion. Skin and subcutaneous tissue disorders: Photosensitivity, urticaria, increased sweating.
Drug Interactions
Additive effects with other CNS depressants (e.g. sedatives, hypnotics, tranquillisers, antianxiety drugs). May interfere with serotonin-enhancing antidepressants (e.g. SSRI) which may result in recurrence of depression and related symptoms.
CIMS Class
Antihistamines & Antiallergics / Antimigraine Preparations / Appetite Enhancers
ATC Classification
R06AX02 - cyproheptadine ; Belongs to the class of other antihistamines for systemic use.
Disclaimer: This information is independently developed by CIMS based on cyproheptadine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in